Document:

Certain
identified information has been omitted because the omitted information is (i) not material and (ii) would likely cause competitive
harm to OncoCyte Corporation if publicly disclosed. Omitted portions of this exhibit are marked [**].

 

Execution
Copy

 

Sublicense
and Distribution Agreement

 

This
Sublicense and Distribution Agreement (“Agreement”), dated and effective as of September 30, 2019 (the
“Effective Date”), is by and among Razor Genomics Inc., a Delaware corporation (“Sublicensor”),
OncoCyte Corporation, a California corporation (“Sublicensee”), and Encore Clinical, Inc., a Delaware
corporation (“Encore”). Sublicensor, Sublicensee and Encore may be referred to herein collectively as
the “Parties” or individually as a “Party”.

 

Preamble

 

WHEREAS,
Sublicensor is the current exclusive licensee under the Amended and Restated Exclusive License Agreement for Gene-Based Assays
for Cancer Diagnosis and Prognosis, dated as of February 15, 2018, by and between The Regents of the University of California,
a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland,
California (94607-5200) (“The Regents”), and acting through the University of California, San Francisco
Office of Technology Management, 185 Berry Street Suite 4603, San Francisco, CA 94107 (the “Licensor”),
and Sublicensor (as amended, the “License Agreement”). Under the License Agreement, Sublicensor has
obtained an exclusive license to Patent Rights (as defined in the License Agreement);

 

WHEREAS,
Sublicensor is also the co-owner, with The Regents, of certain patents and applications licensed by The Regents to Sublicensor
under the License Agreement, which co-owned patents and applications are identified in a schedule attached hereto as Schedule
A (the “Co-Owned Patents and Applications”);

 

WHEREAS,
the Parties are parties to that certain Subscription and Stock Purchase Agreement, dated as of September 4, 2019 (the “SSPA”),
pursuant to which (i) at the initial closing thereunder (the “Initial Closing”), among other matters,
and subject to the terms and conditions therein, Sublicensor agreed to sell to Sublicensee a number of newly issued shares of
Sublicensor preferred stock, constituting 25% of Sublicensor’s outstanding equity on a fully-diluted basis (after giving
effect to the redemption), and (ii) after the Initial Closing, at such times and subject to such conditions as set forth in the
SSPA and the Minority Holder Purchase Agreements, including the exercise of Sublicensee’s purchase option thereunder, Sublicensee
agreed to purchase from Sublicensor’s shareholders and option holders the remaining shares of Sublicensor equity (the consummation
of such transaction, the “Second Closing”); and

 

WHEREAS,
in connection with the transactions contemplated by the SSPA, Sublicensee desires to obtain, and Sublicensor agrees to grant,
a sublicense to the Patent Rights, on and subject to the terms and conditions of the License Agreement and this Agreement;

 

WHEREAS,
Sublicensor also desires to grant a license to Sublicensee, and Sublicensee desires to obtain a license to Sublicensor’s
rights under the Co-Owned Patents and Applications to make, use, Sell, offer for Sale and import Licensed Products and Licensed
Services and to practice Licensed Methods, in the United States and in other countries where Sublicensor and The Regents may lawfully
grant such licenses, only in the Field of Use, as each of those terms are defined and used in, and subject to the terms and conditions,
of the License Agreement.

 

    	 	 	 

    	 

    

 

NOW,
THEREFORE, in consideration of the mutual covenants, terms, and conditions set forth herein, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

 

1. License
Agreement.

 

(a) Sublicensor
has provided Sublicensee with true and complete copies of the License Agreement as of the Effective Date.

 

(b) Sublicensee
acknowledges and agrees that the sublicense granted under Section 2(a) below is subject to, and Sublicensee shall comply with,
all applicable terms and conditions of the License Agreement in accordance with the following schedule:

 

(i) Upon
the Initial Closing, and effective as of the Initial Closing date, without limiting the foregoing, the terms of the License Agreement
are hereby incorporated by reference in this Agreement, together with any necessary conforming changes, and will be effective
as if fully set forth herein; provided that any notices or communications required to be provided to Licensor under any of the
foregoing shall be provided by Sublicensee to Sublicensor. For the avoidance of doubt, Sublicensee shall assume the duties, obligations,
and rights of the Sublicensor in of the License Agreement. Subject to and to the extent permitted under the terms of the License
Agreement, Sublicensee will have the right to control any third party infringement, invalidation or other claims with respect
to the Razor Assay (as such term is defined in the SSPA); provided, that Sublicensee will reasonably consult with Encore
regarding any matters of patent infringement, invalidation and enforcement and give reasonable consideration to Encore’s
input in connection therewith. 

 

(ii) At
any time after the Second Closing, at the sole election of the Sublicensee, Sublicensee will have the right to transfer the License
in full and all related intellectual property rights from Sublicensor to Sublicensee, and upon such transfer all sections of the
License Agreement shall be applicable to the Sublicensee as if it were a Licensee to the License Agreement. If such election is
made by Sublicensee, Sublicensor will promptly obtain for Sublicensee, and Sublicensee shall execute, a Consent to Substitution
of Party Agreement for the License, evidencing the Regents’ approval of Sublicensee as the exclusive licensee under the
License as a party to the License Agreement.

 

(c) Capitalized
terms that are not otherwise defined in this Agreement will have the meanings given to such terms in the License Agreement, or
if not defined therein, in the SSPA.

 

(d) Sublicensor
is responsible for notifying the Regents of this Agreement and providing the Regents a copy and summary of the material terms
of this Agreement within thirty (30) days of the Effective Date, in compliance with Paragraph 3.3 of the License Agreement and
guarantee all monies due the Regents under the Sublicense.

 

2. Grant.

 

(a) Subject
to the terms and conditions of this Agreement and the License Agreement, Sublicensor hereby grants to Sublicensee an exclusive,
worldwide right and sublicense, without the right to grant further sublicenses, except as provided in the License Agreement, under
the Patent Rights to make, use, Sell, offer for Sale and import Licensed Products and Licensed Services and to practice Licensed
Methods, in the United States and in other countries where The Regents may lawfully grant such licenses, only in the Field of
Use.

 

    	 	2	 

    	 

    

 

(b) Subject
to the terms and conditions of this Agreement and the License Agreement, Sublicensor also hereby grants to Sublicensee an exclusive,
worldwide right and sublicense, without the right to grant further sublicenses, except as provided in the License Agreement, under
the Co-Owned Patents and Applications to make, use, Sell, offer for Sale and import Licensed Products and Licensed Services and
to practice Licensed Methods, in the United States and in other countries where Sublicensor may lawfully grant such licenses,
only in the Field of Use in accordance with the terms of the License. The Co-Owned Patents and Applications means the patents
and applications in Schedule A, corresponding foreign patents and applications and any reissues, extensions, substitutions,
continuations, divisions, and continuation-in-part applications, and provisional or nonprovisional applications or other applications
to which any patent or application listed in Schedule A claims priority that are not already included in the definition
of Patent Rights in Section 1.14 of the License are hereby included as Patent Rights under Section 1.14 of the License in this
Agreement.

 

(c) As
among Sublicensee, Sublicensor and Encore, Sublicensee will own, develop and control the commercialization plan and all aspects
of the commercialization of the Razor Assay, not subject to the consent or approval of Sublicensor or Encore.

 

(d) Sublicensee
acknowledges that all rights granted to it by Sublicensor hereunder are subject to all applicable restrictions and limitations
on the rights granted to Sublicensor under the License Agreement, and nothing in this Agreement will be construed to grant to
Sublicensee any rights beyond those that Sublicensor has the right to grant to Sublicensee pursuant to the License Agreement.

 

3. Payments.

 

(a) Upon
execution of this Agreement, Sublicensee shall pay Sublicensor a Sublicense Fee of [**].

 

(b) Sublicensee
is responsible for shall make all required payments under the License Agreement, including those required under Articles 7, 8,
9, and 20 of the License Agreement, together with any necessary conforming changes - but without limiting any additional obligations
will apply to all payments to be made by Sublicensee under this Agreement in the same manner as they apply to all payments to
be made by Sublicensor under the License Agreement. Sublicensee will be solely responsible for payment of any interest, penalties,
administrative costs, costs of collection, and any associated attorneys’ fees Licensor assesses pursuant to the License
Agreement that result from payments Sublicensee fails to timely make.

 

(c) Sublicensee
is responsible for and shall pay any revenue sharing/earnout payments owed by Sublicensor to (i) [**] under
Sublicensor’s agreement with [**] (the “[**] Agreement”) and (ii) former [**] shareholders
under the Agreement and Plan of Merger, dated as of June 23, 2012 (as amended, the “[**]
Agreement”), by and among [**], [**], [**], [**] and for limited purposes, [**] and [**] Sublicensor and Encore
will reasonably cooperate and assist Sublicensee in negotiating an amendment to the Pinpoint Agreement to allow all or a
portion of the consideration thereunder to be payable in shares of Buyer Common Stock (as defined in the SSPA)).

 

(d) Prior
to the Second Closing, Sublicensee will provide Sublicensor with copies of all progress and royalty reports required under the
License Agreement.

 

    	 	3	 

    	 

    

 

(e) Sublicensee
shall pay to the Company Holders (as defined in the SSPA) collectively a quarterly royalty payment (payable within sixty (60)
days after the end of the applicable quarter) based on (i) the Net Sales from the sale of the Razor Assay, less (ii) the amount
of any fees paid under the License Agreement or any other third party license fees or revenue shares paid and other customary
deductions such as discounts, chargebacks and rebates, freight, shipping, and insurance costs, requirement distribution commissions,
taxes, etc. from the sale of the Razor Assay that are not otherwise deducted from Net Sales under the terms of the License Agreement
(provided, that notwithstanding the foregoing or anything to the contrary in the License Agreement, the foregoing quarterly royalty
payment will be paid solely on actual net cash received by Buyer during the applicable quarter) (“Net Cash Revenues”)
as follows:

(i) [**]
of all Net Cash Revenues received by Sublicensee during the duration of this Agreement until Sublicensee has received an aggregate
of [**] in Net Cash Revenues;

 

(ii) [**]
of all Net Cash Revenues received by Sublicensee during the duration of this Agreement in excess of [**] until Sublicensee has
received an aggregate of [**] in Net Cash Revenues; and

 

(iii) [**]
of all Net Cash Revenues received by Sublicensee during the duration of this Agreement in excess of [**].

 

Such
royalty payment shall be allocated among the Company Holders on a pro rata basis based on (i) prior to the Second Closing, the
shares of Sublicensor owned by each such Company Holder at such time and (ii) at or after the Second Closing, the Purchased Shares
(as defined in the SSPA) sold to Sublicensee under the SSPA and the Minority Holder Purchase Agreements.

 

Notwithstanding
the foregoing, the Parties will consider in good faith any appropriate adjustments and structuring changes to the royalty payments
and other payments under this Agreement as required to maintain Sublicensor’s status as an LDT in accordance with CLIA requirements.

 

4. CLIA
Laboratory Costs. Sublicensee hereby agrees that upon the Initial Closing, it will assume the costs associated with the operation
of the Sublicensor’s CLIA laboratory and the commercialization of the Razor Assay for periods from and after the Initial
Closing as follows:

 

(a) Prior
to the Initial Closing, the Parties will amend the Laboratory Agreement between Encore and Sublicensor so that Sublicensee will
become a party thereunder and pay any amounts due by Sublicensor to Encore as laboratory services thereunder incurred after the
Initial Closing. For the avoidance of doubt, the current fees of the Laboratory Agreement paid to Encore will include the following:

 

(i) the
continued involvement by the following individual roles to be solely provided at the sole expense of Encore to operate and maintain
the CLIA lab for the Razor Assay: (A) CLS (60% FTE), manages all daily operational functions and quality assurance and quality
control; (B) Laboratory director; (C) Domain expert, technical/clinical consultant; and (D) Technical supervisor, CLIA regulatory
expert consultant; and 

 

(ii) access
and use of the entire Brisbane facility for all activities at Sublicensee’s discretion, subject to landlord consent.

 

(b) To
the extent that Sublicensee determines that additional support is needed from Encore beyond what is captured in the current Laboratory
Agreement, the Parties will negotiate in good faith a payment scheme in which Sublicensee pays for all reasonable out-of-pocket
costs related to the increased amount of support.

 

    	 	4	 

    	 

    

 

(c) None
of the expenses under the Laboratory Agreement will part of the Clinical Trial expenses covered by the Clinical Trial Expense
Reserve, including provision of the Razor Assay for use in the Clinical Trial in excess of what is currently scoped in the Laboratory
Agreement, or otherwise required to be paid by Sublicensee under the Development Agreement.

 

(d) For
the avoidance of doubt, (i) Sublicensee will not be required to assume any lease of the Sublicensor for the CLIA laboratory with
any of the sublessees or lessors, (ii) Sublicensee shall be entitled to lease laboratory space to the Sublicensor for the Clinical
Trial or any related commercialization of the Razor Assay, (iii) Sublicensee may charge market rent for such space leased pursuant
to clause (ii) above, provided that Sublicensee shall assume the costs of transferring the Clinical Trial to Sublicensee laboratories,
and (iv) if such costs for transferring the Clinical Trial are assumed pursuant to clause (iii) above, Sublicensee will assume
the costs solely related to subletting and/or negotiating early termination of the Brisbane facility lease for Sublicensor’s
laboratory space as incurred by CureSeq, Inc.

 

(e) After
the Second Closing, Sublicensee will have the option at its sole election to continue, renegotiate or terminate the Laboratory
Agreement. The Laboratory Agreement, as amended, will provide that Sublicensee will also be able to terminate the Laboratory Agreement
without further liability if there is a material uncured breach by Encore Clinical thereunder or if there is an event or occurrence
that adversely affects, in any material respect, the Razor Assay, its prospects or its ability to be commercialized.

 

(f) Notwithstanding
the foregoing, for the avoidance of doubt, the Laboratory Agreement, as amended, will provide Sublicensee with customary indemnification
rights from Sublicensor and Encore for the negligence or wrongful acts of Sublicensor, Encore or their respective Representatives
(as defined in the SSPA).

 

5. Additional
Services and Covenants.

 

(a) As
described in the Development Agreement, pursuant to the Consulting Agreement (as defined in the Development Agreement) to be entered
into by Encore and Sublicensee at or prior to the Initial Closing, Encore, through its personnel, will provide consulting services
to or on behalf of Sublicensee in support of, among other matters, the commercialization of the Razor Assay and with respect to
such other matters with respect to Sublicensor’s business as reasonably requested by Sublicensee.

 

(b) Sublicensor
will serve as the laboratory of record for the Razor Assay (i.e., the test report will state “Test performed at Razor Genomics
Inc.”).

 

(c) During
the Term, each Party will maintain insurance as required by the terms of the License Agreement and such other reasonable and customary
insurance to support its business and operations and obligations under this Agreement.

 

6. Intellectual
Property Rights. To the extent permitted under the License Agreement, any and all intellectual property rights developed by
Sublicensee, Sublicensor or Encore (including any inventions, improvements or discoveries) with respect to the Razor Assay in
connection with this Agreement, the Development Agreement, and the Consulting Agreement and any intellectual property rights in
any New Developments as defined in the License Agreement, will be jointly owned by Sublicensee, Sublicensor, and Encore and are
hereby assigned to Sublicensee, Sublicensor, and Encore.

 

    	 	5	 

    	 

    

 

7. Representations
and Warranties; Covenants.

 

(a) Each
Party represents and warrants to the other Party that: (i) it is duly organized and validly existing under the Laws of its jurisdiction;
(ii) it has the requisite power and authority to enter into this Agreement and to perform its obligations hereunder; and (iii)
when executed and delivered by such Party, this Agreement will constitute the legal, valid, and binding obligation of that Party,
enforceable against that Party in accordance with its terms.

 

(b) Sublicensor
represents, warrants, and covenants to Sublicensee that: (i) Sublicensor has the right to grant the sublicense to the Patent Rights
granted to Sublicensee under this Agreement and has obtained any required approvals and consents from the Regents and the Licensor
and complied with all required notices to the Regents under the License Agreement; (ii) Sublicensor will not amend any terms or
conditions of the License Agreement without the prior written consent of Sublicensee (such consent not to be unreasonably withheld,
delayed or conditioned); and (iii) Sublicensor owns and has the right to grant the license granted hereunder to the Co-Owned Patents
and Applications and has no other patents or pending patent applications.

 

(c) Sublicensee
covenants that it will not exercise any of its rights under this Agreement in any manner that would reasonably be expected to
result in Sublicensor being in material breach of any of its obligations under the License Agreement or that otherwise could reasonably
be expected to result in Licensor having a right to terminate the License Agreement.

 

8. Term
and Termination.

 

(a) This
Agreement commences on the Effective Date and continues until the earlier of (i) the expiration or termination of the License
Agreement in accordance with its terms; or (ii) this Agreement’s termination in accordance with this Section 8 (the
“Term”).

 

(b) This
Agreement can be terminated as follows:

 

(i) by
mutual written consent of the Parties;

 

(ii) by
Sublicensee by providing written notice thereof to the other Parties, if there has been a material breach or violation by Encore
or, prior to the Second Closing, the Sublicensor of their respective representations, warranties, covenants or agreements under
this Agreement, the Development Agreement, the Consulting Agreement or the Laboratory Agreement and such breach or violation is
not cured within [**] after written notice of such breach or violation is provided by Sublicensee to Encore;

 

(iii)
by Encore by providing written notice thereof to the other Parties, if there has been a material breach or violation by Sublicensee
of its representations, warranties, covenants or agreements under this Agreement, the Development Agreement, the Consulting Agreement
or the Laboratory Agreement and such breach or violation is not cured within [**] after written notice of such breach or violation
is provided by Encore to Sublicensee; or

 

(iv) by
Sublicensee by providing written notice thereof to the other Parties, if there has been any event, fact, condition, change, circumstance,
occurrence or effect, which, either individually or in the aggregate with all other events, facts, conditions, changes, circumstances,
occurrences or effects, adversely affects, in any material respects, the Razor Assay, it prospects or its ability to be commercialized.

 

    	 	6	 

    	 

    

 

(c) In
the event of the termination of this Agreement, the obligations of the Parties under this Agreement will become null and void,
and there shall be no further liability or obligation on the part of any Party or any of their respective Representatives hereunder.
Notwithstanding anything herein to the contrary, no termination of this Agreement shall affect (i) any obligations of the parties
under Articles 6, 9, and this Article 8, which shall survive any termination of this Agreement or (ii) any Liability of a Party
for a willful breach or violation of this Agreement or any Fraud Claim against such Party, in either case, prior to such termination.

 

9. Miscellaneous.

 

(a) Arbitration.
Any and all disputes, controversies and claims (other than applications for a temporary restraining order, preliminary injunction,
permanent injunction or other equitable relief or application for enforcement of a resolution under this Section 9(a))
arising out of, related to, or in connection with this Agreement or the transactions contemplated hereby (a “Dispute”)
shall be governed by this Section 9(a). A Party must, in the first instance, provide written notice of any Disputes to
the other Parties subject to such Dispute, which notice must provide a reasonably detailed description of the matters subject
to the Dispute. The Parties involved in such Dispute shall seek to resolve the Dispute on an amicable basis within twenty (20)
days of the notice of such Dispute being received by such other Parties subject to such Dispute; the “Resolution Period”);
provided, that if any Dispute would reasonably be expected to have become moot or otherwise irrelevant if not decided within
sixty (60) days after the occurrence of such Dispute, then there shall be no Resolution Period with respect to such Dispute. Any
Dispute that is not resolved during the Resolution Period may immediately be referred to and finally resolved by arbitration pursuant
to the then-existing Expedited Procedures (as defined in the AAA Procedures) of the Commercial Arbitration Rules (the “AAA
Procedures”) of the American Arbitration Association (the “AAA”). Any Party involved in
such Dispute may submit the Dispute to the AAA to commence the proceedings after the Resolution Period. To the extent that the
AAA Procedures and this Agreement are in conflict, the terms of this Agreement shall control. The arbitration shall be conducted
by one arbitrator nominated by the AAA promptly (but in any event within five (5) Business Days) after the submission of the Dispute
to the AAA and reasonably acceptable to each Party subject to the Dispute, which arbitrator shall be a commercial lawyer with
substantial experience arbitrating disputes under license agreements. The arbitrator shall accept his or her appointment and begin
the arbitration process promptly (but in any event within five (5) Business Days) after his or her nomination and acceptance by
the Parties subject to the Dispute. The proceedings shall be streamlined and efficient. The arbitrator shall decide the Dispute
in accordance with the substantive law of the State of Delaware. Time is of the essence. Each Party subject to the Dispute shall
submit a proposal for resolution of the Dispute to the arbitrator within twenty (20) days after confirmation of the appointment
of the arbitrator. The arbitrator shall have the power to order any Party to do, or to refrain from doing, anything consistent
with this Agreement, the SSPA, the other Ancillary Documents and applicable Law, including to perform its contractual obligation(s);
provided, that the arbitrator shall be limited to ordering pursuant to the foregoing power (and, for the avoidance of doubt, shall
order) the relevant Party (or Parties, as applicable) to comply with only one or the other of the proposals. The arbitrator’s
award shall be in writing and shall include a reasonable explanation of the arbitrator’s reason(s) for selecting one or
the other proposal. The seat of arbitration shall be in the State of California, and the language of the arbitration shall be
English.

 

    	 	7	 

    	 

    

 

(b) Governing
Law; Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by,
and construed in accordance with, the laws of the State of Delaware (without giving effect to its choice of law principles). Subject
to Section 9(a), for purposes of any Action arising out of or in connection with this Agreement or any transaction contemplated
hereby or thereby, each of the Parties (a) irrevocably submits to the exclusive jurisdiction and venue of any state or federal
court located in the State of California (and any appellate courts thereof), (b) agrees that service of any process, summons,
notice or document by U.S. registered mail to such Party’s respective address set forth in Section 9(e) shall be
effective service of process for any Action with respect to any matters to which it has submitted to jurisdiction in this Section
9(b), and (c) waives and covenants not to assert or plead, by way of motion, as a defense or otherwise, in any such Action,
any claim that it is not subject personally to the jurisdiction of such court, that the Action is brought in an inconvenient forum,
that the venue of the Action is improper or that this Agreement or the subject matter hereof or thereof may not be enforced in
or by such court, and hereby agrees not to challenge such jurisdiction or venue by reason of any offsets or counterclaims in any
such Action. The Parties hereby knowingly, voluntarily and intentionally waive the right
any may have to a trial by jury in respect to any litigation based hereon, or arising out of, under, or in connection with this
Agreement and any agreement contemplated to be executed in connection herewith, or any course of conduct, course of dealing, statements
(whether verbal or written) or actions of any Party in connection with such agreements.

 

(c) Remedies.
Except as specifically set forth in this Agreement, any Party having any rights under any provision of this Agreement will have
all rights and remedies set forth in this Agreement and all rights and remedies which such Party may have been granted at any
time under any other contract or agreement and all of the rights which such Party may have under any applicable Law. Except as
specifically set forth in this Agreement, any such Party will be entitled to (a) seek to enforce such rights specifically, without
posting a bond or other security or proving damages or that monetary damages would be inadequate, (b) to recover damages by reason
of a breach of any provision of this Agreement and (c) to exercise all other rights granted by applicable Law. The exercise of
any remedy by a Party will not preclude the exercise of any other remedy by such Party.

 

(d) Further
Assurances. Each Party shall, upon the reasonable request of another Party, promptly execute such documents and perform such
acts as may be necessary to give full effect to the terms of this Agreement.

 

(e) Notices.
Any notice, request, instruction or other document to be given hereunder by a party hereto shall be in writing and shall be deemed
to have been given, (i) when received if given in person or by courier or a courier service, (ii) on the date of transmission
if sent by facsimile or email (with affirmative confirmation of receipt, and provided, that the party providing notice shall within
two (2) Business Days provide notice by another method under this Section 9(e) or (iii) three (3) Business Days after being
deposited in the U.S. mail, certified or registered mail, postage prepaid:

 

	If
    to Encore or, at or prior to the Second Closing, Sublicensor, to:	with
    a copy (which will not constitute notice) to:
	 	 
	Razor
    Genomics Inc.	Latham &
    Watkins LLP
	150 N. Hill
    Drive, Suite 14	140 Scott Drive
	Brisbane, CA
    94005	Menlo Park,
    CA 94025
	Attn: Michael
    Mann, CEO	Attn: Benjamin
    A. Potter, Esq.
	Telephone No:
    [**]	Facsimile No.:
    [**]
	Email: [**]	Telephone No:
    [**]
	 	Email: [**]

 

    	 	8	 

    	 

    

 

	If
    to Sublicensee or, after the Second Closing, Subliensor, to:	with a copy
    (which will not constitute notice) to:
	 	 
	OncoCyte
    Corporation	Ellenoff Grossman
    & Schole LLP
	1010 Atlantic
    Avenue, Suite 102	1345 Avenue
    of the Americas, 11th Floor
	Alameda, California
    94501	New York, New
    York 10105
	Attn: Albert
    P. Parker, COO	Attn: Matthew
    A. Gray, Esq.;
	Telephone No:
    [**]	 Robert
    Charron, Esq.
	Email: [**]	Facsimile No.:
    [**]
	 	Telephone No.:
    [**]
	 	Email: [**]

 

or
to such other individual or address as a party hereto may designate for itself by notice given as herein provided.

 

(f) Entire
Agreement. This Agreement, together with any other documents referenced or incorporated herein by reference (including the
License Agreement, the SSPA, the Development Agreement, the Consulting Agreement and the Laboratory Agreement (as amended)) and
all related schedules, constitutes the sole and entire agreement of the Parties with respect to the subject matter contained herein,
and supersedes all prior and contemporaneous understandings, agreements, representations, and warranties, both written and oral,
with respect to such subject matter.

 

(g) Assignment;
Third Party Beneficiaries. This Agreement may not be assigned by any Party without the prior written consent of the other
Parties hereto, and any attempted assignment in violation of this Section 9(g) will be null and void ab initio;
provided, however, that upon or after the Second Closing, each of Sublicensee and Sublicensor may assign its rights
and obligations hereunder: (i) to any Affiliate of such Party, as applicable (provided, that such assigning Party shall remain
primarily responsible for its obligations hereunder); (ii) to any Person acquiring all or substantially all of the assets of Sublicensee
and its Subsidiaries taken as a whole or all or substantially all of the assets of Sublicensor and its Subsidiaries taken as a
whole or a majority of the outstanding equity securities of Sublicensee or Sublicensor (whether by stock purchase, merger, consolidation
or otherwise); provided, that the assignee expressly assumes the obligations of Sublicensee or Sublicensor, as applicable,
hereunder; or (iii) as security to any Person providing debt financing to Sublicensee or its Affiliates for any of the transactions
contemplated by the SSPA or this Agreement. Subject to the preceding sentence, this Agreement will apply to, be binding in all
respects upon and inure to the benefit of the successors and permitted assigns of each Party.

 

(h) No
Third Party Beneficiaries. This Agreement is for the sole benefit of the Parties and their successors and permitted assigns
and nothing herein expressed or implied shall give or be construed to give to any Person, other than the Parties and such successors
and permitted assigns, any legal or equitable rights hereunder. Without limiting the foregoing, the Minority Holders shall not
have any right hereunder to make any claims against Sublicensee with respect to Section 3(e).

 

(i) Amendment;
Modification; Waiver. This Agreement may only be amended, modified, or supplemented by an agreement in writing signed by each
of the Parties. No waiver by any Party of any of the provisions hereof will be effective unless expressly set forth in writing
and signed by the waiving Party. Except as otherwise set forth in this Agreement, no failure to exercise, or delay in exercising,
any rights, remedy, power, or privilege arising from this Agreement will operate or be construed as a waiver thereof; nor will
any single or partial exercise of any right, remedy, power, or privilege hereunder preclude any other or further exercise thereof
or the exercise of any other right, remedy, power, or privilege.

 

(j) Severability.
If any term or provision of this Agreement is invalid, illegal, or unenforceable in any jurisdiction, such invalidity, illegality,
or unenforceability will not affect any other term or provision of this Agreement or invalidate or render unenforceable such term
or provision in any other jurisdiction. Upon a determination that any term or other provision is invalid, illegal, or unenforceable,
the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely
as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated
to the greatest extent possible.

 

(k)
Counterparts. This Agreement may be executed in counterparts, each of which will be deemed an original, but all of which
together will be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, email, or other
means of electronic transmission will be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

 

(l) Regents
and Licensor Approval. Notwithstanding anything to the contrary contained in this Agreement, the terms and conditions of this
Agreement will be subject in all respects to the receipt by the Parties of the consent of the Regents and the Licensor to the
extent required by the License Agreement. Sublicensor is responsible for obtaining and shall obtain approval of the Regents and
the Licensor for this Sublicense Agreement and procure and any necessary written consents. Failure to obtain any required approvals
and written consents from the Regents and the Licensor shall be a material breach of this Agreement by Sublicensor.

 

{Remainder
of Page Left Blank; Signature Page Follows}

 

    	 	9	 

    	 

    

 

IN
WITNESS WHEREOF, the Parties have caused this Agreement to be executed as of the Effective Date by their respective officers thereunto
duly authorized.

 

	 	Sublicensee:
	 	 	 
	 	ONCOCYTE CORPORATION
	 	 	 
	 	By: 	/s/
    Ron A. Andrews
	 	Name:	Ron A. Andrews
	 	Title:	President and
    Chief Executive Officer
	 	 	
	 	Encore:
	 	 	 
	 	ENCORE CLINICAL, INC. 
	 	 	 
	 	By:	/s/
    Michael Mann
	 	Name:	Michael Mann
	 	Title:	Chief Executive
    Officer
	 	 	 
	 	Sublicensor:
	 	 	 
	 	RAZOR GENOMICS INC.
	 	 	 
	 	By:	/s/
    Michael Mann
	 	Name:	Michael Mann
	 	Title:	Chief Executive
    Officer

 

    	 	10	 

    	 

    

 

Schedule
A

 

	1.	U.S.
    Pat. App. No. 13/539,278 – Pat. No. 9,476,098
	2.	PCT/US2012/045136
	3.	PCT US/2012/045139
	4.	AU2012279173; AU2012279173
	5.	EP128074291; EP2726635
	6.	HK141108110; HK1197431
	7.	AT128074291; AT2726635
	8.	BE128074291; BE2726635
	9.	DK128074291; DK2726635
	10.	ES128074291; ES2726635
	11.	FI128074291; FI2726635
	12.	GR128074291; GR2726635
	13.	HU128074291; HU2726635
	14.	IE128074291; IE2726635
	15.	IT128074291; IT2726635
	16.	NL128074291; NL2726635
	17.	NO128074291; NO2726635
	18.	PL128074291; PL2726635
	19.	SE128074291; SE2726635
	20.	CH128074291; CH2726635
	21.	DE128074291; DE
    602012039575.3
	22.	FR128074291; FR2726635
	23.	GB128074291; GB2726635
	24.	CN201280033168;
    CN103998622
	25.	HUE036585
	26.	JP5988934
	27.	JP201614682
	28.	JP201052862
	29.	ES2658921

 

    	 	11Certain
identified information has been omitted because the omitted information is (i) not material and (ii) would likely cause competitive
harm to OncoCyte Corporation if publicly disclosed. Omitted portions of this exhibit are marked [**].

 

LABORATORY
AGREEMENT

 

THIS
LABORATORY AGREEMENT (this “Agreement”) is made as of August 15, 2015 (the “Effective Date”) among
Encore Clinical, Inc., a Delaware corporation (“Encore”), and Razor Genomics, Inc., a Delaware corporation
(“Razor”). Each of Encore and Razor is hereinafter referred to as a “Party” and collectively
as the “Parties”.

 

RECITALS

 

WHEREAS,
Encore has obtained an exclusive, worldwide, and royalty-bearing license from the Regents of the University of California (the
“License”) to a 14-gene assay that predicts clinical outcome in early stage lung cancer (the “Assay”);

 

WHEREAS,
Encore has established a CLIA-certified laboratory (the “CLIA Laboratory”) to perform the Assay for clinical use and
in connection with a clinical trial involving the use of the Assay to identify high-risk lung cancer patients for whom chemotherapy
or other specific therapies may be appropriate to improve outcomes (the “Study”); and

 

NOW,
THEREFORE, in consideration of the premises and of the mutual covenants and agreements herein contained, the Parties agree as
follows:

 

ARTICLE
1

 

DEFINITIONS

 

The
following terms, whenever used in this Agreement, shall have the following meanings:

 

“Affiliate”
means, with respect to a Party to this Agreement, any current or future entity which controls, is controlled by, or is under common
control with such Party for so long as such control is maintained. For purposes of this definition only, “control”
means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of
a Person, whether through the ownership of voting securities, as trustee or executor, by contract or otherwise, including, without
limitation, the ownership, directly or indirectly, of securities having the power to elect a majority of the board of directors
or similar body governing the affairs of such Person.

 

“Business
Day” means any day that is not a Saturday, a Sunday or holiday on which banking institutions located in New York, New
York are authorized or obligated by Law or executive order to close.

 

“CLIA”
means the Clinical Laboratory Improvement Amendments of 1988, as amended, as set forth in 42 CFR part 493.

 

    	 

    	 

    

 

“Confidential
Information” means information relating to all non-public information provided by one Party to another Party.

 

“Control”
or “Controlled” shall mean with respect to Know-How or Patents, that the applicable Party has licensed (or
otherwise obtained rights to or under) such Know-How or Patents from a third party and such Party has the right to grant sublicenses
to such Know-How or Patents without any additional payments due to Third Parties from whom such rights are so obtained, unless
the Party receiving such sublicense.

 

“Field”
means the performance of CLIA-certified clinical or diagnostic testing services performed on patient samples.

 

“Governmental
Authority” means any applicable supra-national, federal, national, regional, state, provincial, or local government,
governmental, regulatory or administrative authority, agency or commission or any court, tribunal, or judicial or arbitral body,
including the

 

U.S.
Food and Drug Administration or the China Food and Drug Administration that regulates or otherwise exercises authority with respect
to the Development or Commercialization of the Assay.

 

“Intellectual
Property” means the Patents and the Know-How Controlled by a Party during the Term of this Agreement.

 

“Know-How”
shall mean any and all confidential information, trade secrets, technology, know-how, genetic information (including information
relating to any impairment, variance, or mutation thereof) discoveries, algorithms, unpatented inventions, developments, improvements,
techniques, methods, test methods, processes, data (including development data), instructions, formulae, drawings and specifications,
whether or not patentable or protectable.

 

“Laboratory
Services” means the performance of CLIA-certified clinical or diagnostic testing services consisting of performance
of the Assay for use in the Field.

 

“Patents”
means (i) unexpired letters patent (including without limitation inventor’s certificates), including without limitation
any substitution, extension, registration, confirmation, reissue, re-examination, renewal, or any like filing thereof, and (ii)
pending applications for letters patent, including without limitation any continuation, divisional, or continuation-in-part thereof,
and any provisional or nonprovisional applications in each case anywhere in the world.

 

“Person”
means an individual, partnership, company, corporation, limited liability company, association, joint stock company, trust, joint
venture, organization, business organization, estate, union and any authority or any department, agency or political subdivision
thereof.

 

    	 	2	 

    	 

    

 

ARTICLE
2

 

LABORATORY
ACQUISITION OPTION

 

2.1
Laboratory Acquisition Option. In consideration of 1,500,000 shares of Razor common stock at the closing of this Agreement
(the “Option Consideration”), Encore hereby grants to Razor and Razor accepts an exclusive option to acquire
the CLIA Laboratory, including all rights to the Assay, in exchange for $500,000.00 during the Option Period as set forth in this
Article 2 (the “Laboratory Acquisition Option”).

 

2.2
Exercise. For the period starting from the first anniversary of the Effective Date and continuing for 90 days thereafter
(the “Option Period”), Razor will have the right to exercise the Laboratory Acquisition Option by delivering
to Encore a written notice stating that Razor is exercising its option hereunder. Within 60 days after Encore’s receipt
of such notice, Razor shall complete payment of $500,000.00 and Encore shall transfer to Razor all right, title and interest in
and to the physical assets and materials, agreements and other assets owned by Encore that are specifically related to the CLIA
Laboratory and the Assay.

 

2.3
Patent Costs. Beginning on the Effective Date and continuing until the exercise of the Laboratory Contribution Option,
Razor agrees to reimburse Encore for of all royalties, license fees, milestone fees and patent prosecution costs related to the
maintenance of the License.

 

ARTICLE
3

 

LABORATORY
MANAGEMENT PAYMENTS

 

3.1
Payments.
To support Encore’s ongoing management of the CLIA Laboratory, including but not limited to performance of Laboratory Services,
Razor shall make the following payments to Encore (the “Laboratory Management Payments”):

 

	 	 	Payment due date	 	Amount due
	(a)	 	Effective Date	 	USD 450,000
	(b)	 	The first anniversary of the Effective Date	 	USD 300,000
	(c)	 	The second anniversary of the Effective Date	 	USD 300,000
	(d)	 	The third anniversary of the Effective Date	 	USD 300,000
	(e)	 	The fourth anniversary of the Effective Date	 	USD 300,000

 

3.2
Timing of Laboratory Management Payments. Payments due to Encore pursuant to Section 3.1 shall be paid in full by Razor
to Encore’s designated bank account within thirty (30) days after the occurrence of the applicable due date set forth above.

 

    	 	3	 

    	 

    

 

ARTICLE
4

 

INTELLECTUAL
PROPERTY OWNERSHIP

 

4.1
Ownership of Inventions. All inventions, discoveries, ideas, procedures, improvements in Know-How, new uses, processes
and compounds involving the Assay which are conceived or reduced to practice during the Term of this Agreement (“Inventions”),
whether patentable or not, shall be and remain the property of Razor. To the extent necessary to effect the intent of this Agreement,
Razor hereby grants to Encore a non-exclusive, fully-paid, royalty-free license to make, use, sell, offer for sale and import
the Inventions.

 

ARTICLE
5

 

CONFIDENTIALITY

 

5.1
Use, Nondisclosure. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties,
each Party agrees that, during the Term of this Agreement and for five (5) years thereafter, such Party (the “Receiving
Party”) shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose, other
than as expressly provided for in this Agreement, any Confidential Information furnished to it by or on behalf of the other Party
(the “Disclosing Party”) whether through oral, electronic, graphic, or other tangible or intangible means pursuant
to this Agreement. The Receiving Party may use such Confidential Information only to the extent required to accomplish the purposes
of this Agreement. The Receiving Party will use at least the same standard of care as it uses to protect proprietary or confidential
information of its own to ensure that its, and its Affiliates, employees, agents, consultants and other representatives do not
disclose or make any unauthorized use of the Confidential Information. The Receiving Party will promptly notify the Disclosing
Party upon discovery of any unauthorized use or disclosure of the Disclosing Party’s Confidential Information.

  

5.2
Exclusions. Confidential Information shall not include any information which the Receiving Party can prove by competent
evidence: (a) is now, or hereafter becomes, through no act or failure to act on the part of the Receiving Party, generally known
or available; (b) is known by the Receiving Party at the time of receiving such information, as evidenced by its written records;
(c) is hereafter furnished to the Receiving Party by a third party, as a matter of right and without restriction on disclosure;
or (d) is independently discovered or developed by the Receiving Party, without the use of Confidential Information of the Disclosing
Party, as evidenced by the Receiving Party’s written records maintained in the ordinary course of business.

 

5.3
Necessary Disclosures. Each Party may disclose Confidential Information of another Party in the following instances:

 

(a)
complying with applicable court orders, governmental regulations, or rules of a securities exchange provided that, in the event
a Party is required to make a disclosure of another Party’s Confidential Information it will, except where impracticable,
give reasonable advance notice to the other Party of such disclosure and use efforts to secure confidential treatment of such
information at least as diligent as such Party would use to protect its own confidential information, but in no event less than
commercially reasonable efforts;

 

    	 	4	 

    	 

    

 

(b)
disclosure to Affiliates, investors, licensees, acquirers, contractors, employees and consultants who need to know such information
and who are directly involved in the Study or Services in accordance with this Agreement, on the condition that any such third
parties agree to be bound by confidentiality and non-use obligations that are no less stringent than the terms of this Agreement;
and

 

(c)
disclosure to third parties in connection with due diligence or similar investigations by such third parties, provided, in each
case, that any such third party agrees to be bound by reasonable obligations of confidentiality and non-use.

 

5.4
Termination or Expiry. At the conclusion of this Agreement, each Party shall within fifteen (15) days of such termination
or expiry, either return the other Parties’ Confidential Information in its possession (including all copies) or shall,
at the disclosing Party’s direction, destroy such Confidential Information (including all copies) and certify its destruction
to the disclosing Party, except that each Party may keep one (1) archival copy to confirm compliance with its obligations hereunder.

 

5.5
Publicity. The Parties agree that no public disclosure, publicity release or announcement concerning the transactions contemplated
hereby will be issued without the advance written consent of the other Parties except as such disclosure, release or announcement
may be required (a) by applicable laws, (b) for filings with governmental agencies, (c) for prosecuting or defending litigation,
and (d) for complying with applicable governmental regulations, court orders, and legal requirements, including filings with the
U.S. Securities Exchange Commission or rules of a securities exchange, and with regulatory authorities, in each of which cases
the Party required to make such disclosure, release or announcement will, to the extent reasonably practicable before making any
such disclosure, release or announcement, afford the other Parties with a reasonable opportunity to review and comment upon such
release or announcement and use reasonable efforts to seek confidential treatment of such information.

  

ARTICLE
6

 

ADDITIONAL
AGREEMENTS OF THE PARTIES

 

6.1
Compliance with Law. Each Party will comply in all material respects with all applicable laws in performing its
obligations and exercising its rights under this Agreement.

 

ARTICLE
7

 

REPRESENTATIONS
AND WARRANTIES

 

7.1
By All Parties. Each Party represents and warrants the following:

 

(a)
it is duly organized, validly existing, and in good standing under the laws of the state and/or nation of its organization;

 

    	 	5	 

    	 

    

 

(b)
it has all requisite corporate power and authority to enter into this Agreement and perform its obligations hereunder, and it
has taken all necessary corporate action on its part required to authorize the execution and delivery of the Agreement and the
performance of its obligations hereunder;

  

(c)
the Agreement has been duly executed and delivered on behalf of it, and constitutes a legal, valid, and binding obligation of
such Party and is enforceable against it in accordance with its terms;

 

(d)
the execution, delivery, and performance of this Agreement by it does not, and the consummation of the transactions contemplated
hereby will not, violate or conflict with any provisions of its organizational documents, bylaws, any law or regulation applicable
to it, or any agreement, instrument, order, judgment, or decree to which it is a party or by which it is bound that would materially
affect its ability to consummate the transaction contemplated hereby or impair the rights being granted to the other Party; and

  

(e)
all necessary consents, approvals, and authorizations of all Governmental Authorities and other third parties required to be obtained
by such Party in connection with the entry into this Agreement have been obtained.

 

7.2
Foreign Corrupt Practices Act. In the performance of its obligations under this Agreement, none of the Parties shall take
any action or otherwise act in any manner reasonably likely to render such other Party liable for a violation of the United States
Foreign Corrupt Practices Act of 1977, as amended, which prohibits the offering, giving or promising to offer or give, directly
or indirectly, money or anything of value to any official of a government, political party or instrumentality thereof in order
to assist a Party in obtaining or retaining business (or otherwise breach any other applicable laws relating to bribery and corruption).

 

7.3
IMPLIED WARRANTIES. EXCEPT AS EXPRESSLY PROVIDED IN THIS ARTICLE 7, NONE OF THE PARTIES MAKES ANY REPRESENTATIONS OR WARRANTIES
AS TO ITS INTELLECTUAL PROPERTY OR ANY OTHER MATTER, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR
OTHERWISE, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY AND ALL IMPLIED OR STATUTORY WARRANTIES, INCLUDING, WITHOUT LIMITATION, ALL
IMPLIED WARRANTIES OF TITLE, NON-INFRINGEMENT, MERCHANTABILITY, AND FITNESS FOR A PARTICULAR PURPOSE.

 

ARTICLE
8

 

INDEMNIFICATION

 

8.1
Indemnity by Encore. Encore shall indemnify the JV and its directors, officers, employees and agents from any costs, damages,
liabilities or expenses (including reasonable legal fees and expenses) in connection with claims or actions brought by third parties
(collectively, “Losses”) to the extent arising from the breach by or on behalf of Encore of its representations,
warranties or obligations hereunder, or the negligence, gross negligence or willful misconduct of Encore, its Affiliates, independent
contractors or sublicensees.

 

    	 	6	 

    	 

    

 

8.2
Indemnity by Razor. Razor shall indemnify Encore and its directors, officers, employees and agents from any Losses to the
extent arising from the breach by or on behalf of Razor of its representations, warranties or obligations hereunder, or the negligence,
gross negligence or willful misconduct of Razor, its Affiliates or independent contractors.

 

8.3
Conditions of Indemnification. The indemnifying Party’s indemnity obligations as provided for in this Article 8 shall
be conditioned upon the following:

 

(a)
the indemnified Party providing prompt written notice of the applicable claim to the indemnifying Party;

  

(b)
the indemnified Party permitting the indemnifying Party to have sole control over the investigation and defense of the applicable
claim provided that the indemnifying Party shall not settle any claim without the indemnified Party’s prior written consent,
which consent shall not be unreasonably withheld or delayed and which consent shall be provided or withheld in any event within
ten (10) days after the indemnified Party’s receipt of such settlement proposal;

 

(c)
the indemnified Party reasonably cooperating with the indemnifying Party in the investigation and defense of such claim;

 

(d)
the indemnified Party may not admit liability or wrongdoing on behalf of the other Party without the prior written consent of
the other Party; and

 

(e)
the indemnified Party’s agreement not to compromise or otherwise settle any such claim without the indemnifying Party’s
prior written consent, which consent shall not be unreasonably withheld or delayed.

 

8.4
Limitation of Liability. NO PARTY SHALL BE LIABLE TO THE OTHER PARTIES FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL,
OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH
DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 8.4 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS
OR OBLIGATIONS OF ANY PARTY UNDER ARTICLE 8, OR DAMAGES AVAILABLE FOR A BREACH OF CONFIDENTIALITY OBLIGATIONS IN ARTICLE 5.

  

ARTICLE
9

 

TERM
AND TERMINATION

  

9.1
Term. This Agreement shall be effective as of the Effective Date and, unless earlier terminated in accordance with other
provisions herein, shall remain in effect until the fifth anniversary of the Effective Date (the “Term”).

 

9.2
Termination for Material Breach. Any Party may terminate this Agreement if another Party materially breaches this Agreement
and such breaching Party fails to cure the breach within thirty (30) days after receipt of written notice from a non-breaching
Party, such notice specifying in detail the nature of the breach.

 

    	 	7	 

    	 

    

 

9.3
Termination for Default. Any Party may terminate this Agreement if any other Party becomes bankrupt or insolvent, or is
the subject of proceedings for liquidation or dissolution any of which results in an inability of such other Party to perform
the functions of its business in their ordinary course, or ceases to carry on business or becomes unable to pay its debts as and
when they become due and payable.

 

9.4
Effect of Termination. In the event of any termination of this Agreement pursuant to Article 9, all rights and obligations
of the Parties hereunder shall terminate without any liability on the part of any Party in respect thereof, except that (a) the
obligations of the Parties under Articles 4, 5, 8 9 and 10 of this Agreement shall remain in full force and effect and (b) such
termination shall not relieve any Party of any liability for any fraud, intentional misrepresentation or criminal or willful misconduct,
or a breach of the terms and provisions contained in this Agreement arising prior to termination.

  

ARTICLE
10

 

MISCELLANEOUS

 

10.1
Entire Agreement. This Agreement constitutes the entire agreement of the Parties hereto with respect to the subject matter
hereof and thereof and supersedes all prior agreements and undertakings, both written and oral, among the Parties with respect
to the subject matter hereof and thereof.

 

10.2
Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any
law or public policy, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect for
so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse
to any Party hereto. Upon a determination that any term or other provision is invalid, illegal or incapable of being enforced,
the Parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as
closely as possible in an enforceable manner in order that the transactions contemplated hereby are consummated as originally
contemplated to the greatest extent possible.

 

10.3
Amendment and Waiver. This Agreement may not be amended, supplemented or otherwise modified except in a written instrument
executed by all Parties. Any delay in enforcing a Party’s rights under this Agreement or any waiver as to a particular default
or other matter shall not constitute a waiver of such Party’s rights to the future enforcement of its rights under this
Agreement unless such Party provides an express written and signed waiver as to a particular matter for a particular period of
time. No waiver by any of the Parties of any default, misrepresentation or breach of warranty or covenant hereunder, whether intentional
or not, shall be deemed to extend to any prior or subsequent default, misrepresentation or breach of warranty or covenant hereunder
or affect in any way any rights arising by virtue of any prior or subsequent such occurrence.

 

    	 	8	 

    	 

    

 

10.4
Successor and Assigns. Except as provided herein, this Agreement shall be binding upon and inure to the benefit of the
Parties hereto and their respective successors and permitted assigns. No Party may assign (by contract, stock sale, operation
of law or otherwise) either this Agreement or any of its rights, interests or obligations hereunder without the express prior
written consent of the other Parties, and any attempted assignment, without such consent, shall be null and void; provided that
each Investor shall be permitted to assign this Agreement in whole or in part to (a) one or more Affiliates of such Investor or
(b) a successor in interest (or its equivalent) of all or substantially all of its capital stock or relevant assets in the event
of a merger, acquisition, consolidation or change of control. No assignment by any Party shall relieve such Party from any of
its obligations hereunder.

 

10.5
Notices. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (a) upon
personal delivery to the Party hereto to be notified; (b) when sent by confirmed facsimile if sent during normal business hours
of the recipient, and if not, then on the next Business Day; (c) five (5) Business Days after having been sent by registered or
certified mail, return receipt requested, postage prepaid; or (d) one (1) Business Days after deposit with a nationally recognized
overnight courier, specifying next day delivery, with written verification of receipt.

  

10.6
Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware
applicable to contracts executed in and to be performed in that State, without regard to the principles of conflict of laws of
the State of Delaware or any other jurisdiction. The Convention on Contracts for the International Sale of Goods shall not apply
to this Agreement. Each of the parties hereto irrevocably consents to the exclusive jurisdiction and venue of any court within
the State of Delaware, for the purposes of seeking any injunctive relief or the enforcement of an arbitral award, agrees that
process may be served upon it in any manner authorized by the Laws of the State of Delaware, and waives and covenants not to assert
or plead any objection which it might otherwise have to such jurisdiction, venue and such process.

 

10.7
Dispute Resolution. If any dispute arises relating to this Agreement, prior to instituting any termination under Article
9 or any lawsuit or other dispute resolution process on account of such dispute, the Parties will attempt in good faith to settle
such dispute first by negotiation and consultation between themselves, including referral of such dispute to the CEOs of the Parties.
If the CEOs are unable to resolve such dispute or agree upon a mechanism to resolve such dispute within thirty (30) days after
such matter is first submitted to them for resolution, then either Party may then submit such issue for resolution by arbitration.
Any arbitration under this Section 10.7 shall be conducted by Judicial Arbitration and Mediation Services (“JAMS”)
in [New York, New York] in accordance with the applicable JAMS rules by a single arbitrator. The arbitrator shall be provided
by JAMS and appointed by mutual agreement of the Parties, or if the Parties cannot agree within thirty (30) days of the initial
demand for arbitration, the arbitrator shall be selected in accordance with the Rules. If the Parties are unable to agree on an
arbitrator, the arbitrator shall be selected by the chief executive of the New York office of JAMS. The Parties agree that the
arbitrator shall have the power to resolve any disputes to be resolved pursuant to this Section 10.7 based on principles of fairness
and equity. Each Party shall bear its own costs and expenses in connection with the arbitration; however, the Parties agree that,
to the extent permitted by law, the arbitrator may award reasonable attorneys’ fees to the prevailing party. Other costs
of the arbitration, including the cost of any record or transcripts of the arbitration, JAMS’ administrative fees, the fee
of the arbitrator, and all other fees and costs, shall be borne equally by both Parties. Judgment on the award rendered by the
arbitrator may be entered in any court having jurisdiction, in accordance with Section 10.6 of this Agreement. This agreement
to arbitrate is intended to be the exclusive method for resolving any and all claims by the Parties against each other for payment
of damages under this Agreement; provided, however, that neither this Agreement nor the submission to arbitration shall limit
the Parties’ right to seek provisional relief, including without limitation injunctive relief, in any court of competent
jurisdiction, in accordance with Section 10.6 of this Agreement. Seeking any such relief shall not be deemed to be a waiver of
such Party’s right to compel arbitration. The Parties further agree that any arbitration shall be conducted on an individual
basis, and no claims may be arbitrated on a class or collective basis. The Parties further agree that any arbitration shall be
conducted on an individual basis, and no claims may be arbitrated on a class or collective basis.

 

    	 	9	 

    	 

    

 

10.8
Interpretation and Rules of Construction. In this Agreement, except to the extent otherwise provided or that the context
otherwise requires:

 

(a)
when a reference is made in this Agreement to an Article or Section, such reference is to an Article or Section of this Agreement
unless otherwise indicated;

 

(b)
the headings for this Agreement are for reference purposes only and do not affect in any way the meaning or interpretation of
this Agreement;

 

(c)
whenever the words “include,” “includes” or “including” are used in this Agreement, they are
deemed to be followed by the words “without limitation”;

 

(d)
the words “hereof,” “herein” and “hereunder” and words of similar import, when used in this
Agreement, refer to this Agreement as a whole and not to any particular provision of this Agreement;

 

(e)
the definitions of terms contained in this Agreement are applicable to the singular as well as the plural forms of such terms;

 

(f)
any law defined or referred to herein or in any agreement or instrument that is referred to herein means such law or statute as
from time to time amended, modified or supplemented, including by succession of comparable successor laws;

 

(g)
references to a Person are also to its successors and permitted assigns; and

 

(h)
the use of “or” is not intended to be exclusive unless expressly indicated otherwise.

 

10.9
Execution and Counterparts. This Agreement may be executed and delivered (including by facsimile transmission or portable
document format (“.pdf”)) in one or more counterparts, and by the different parties hereto in separate counterparts,
each of which when executed shall be deemed to be an original, but all of which taken together shall constitute one and the same
Agreement.

 

10.10
Force Majeure. If a Party is prevented from complying, either totally or in part, with any of the terms or provisions set
forth herein by reason of force majeure, including, by way of example and not of limitation, fire, flood, explosion, storm, earthquake,
strike, lockout or other labor dispute, riot, war, rebellion, terrorist act, accidents, acts of God, failure of suppliers or any
other similar cause, in each case to the extent beyond its reasonable control, said Party will promptly provide written notice
of same to the other Parties. Such notice will identify the requirements of this Agreement or such of its obligations as may be
affected, and such obligations will be suspended during the period of such disability, provided that the Party prevented from
performing hereunder will use reasonable efforts to remove such disability and will continue performance whenever such causes
are removed. The Party so affected will give to the other Party a good faith estimate of the continuing effect of the force majeure
condition and the duration of the affected Party’s nonperformance.

 

10.11
Use of Names. No Party will use the name or trademark of any other Party in relation to this Agreement in any advertising,
press release or other form of publicity without the prior written permission of such Party. This restriction shall not apply
to materials used by either Party solely for financing purposes or to documents available to the public that identify the existence
of the Agreement.

 

[Remainder
of page intentionally left blank]

 

    	 	10	 

    	 

    

 

IN
WITNESS WHEREOF,
the Parties hereto have executed
this Laboratory Agreement on the
day and year first
above written.

 

	 	ENCORE:
	 	 	 
	 	ENCORE
    CLINICAL, INC.
	 	 	 
	 	By:	/s/
    David Jablons
	 	Name:	David
    Jablons
	 	Its:	Director

 

    	 	11	 

    	 

    

 

IN
WITNESS WHEREOF,
the Parties hereto have executed
this Laboratory Agreement on the
day and year first
above written.

 

	 	RAZOR:
	 	 	 
	 	RAZOR
    GENOMICS, INC.
	 	 	 
	 	By:	/s/
    Michael Mann
	 	Name:	Michael
    Mann
	 	Its:	CEO

 

    	 	12	 

    	 

    

 

AMENDMENT
TO THE LABORATORY AGREEMENT

 

This
is an Amendment (“Amendment”) to that certain Laboratory Agreement (the “Agreement”) dated
August 15, 2015 Encore Clinical, Inc., a Delaware corporation (“Encore”), and Razor Genomics, Inc., a Delaware
corporation (“Razor”). Each of Encore and Razor is hereinafter referred to as a “Party”
and collectively as the “Parties”.

 

WHEREAS,
the Parties desire to amend the Agreement as set forth herein.

  

NOW
THEREFORE, in consideration of the foregoing premises and certain other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Parties hereto further agree as follows:

  

1.
Section 2.2 of the Agreement shall be deleted and replaced in its entirety with the following:

 

“Exercise. For the period starting from the first anniversary of the Effective Date
and continuing for 90 days thereafter (the “Option Period”), Razor will have the right to exercise the Laboratory
Acquisition Option by delivering to Encore a written notice stating that Razor is exercising its option hereunder (the “Option
Notice”). Within 60 days after Encore’s receipt of such notice, Razor shall complete payment of $500,000.00 (the
“Exercise Consideration”) and Encore shall transfer to Razor all right, title and interest in and to the physical
assets and materials, agreements and other assets owned by Encore that are specifically related to the CLIA Laboratory and the
Assay (the “Laboratory Assets”). In the event that Razor is unable to complete payment of the full Exercise
Consideration within 60 days of delivering the Option Notice to Encore, Encore shall transfer to Razor only the License. Transfer
of the reminder of the Laboratory Assets shall occur within 60 days after completion of payment of the full Exercise Consideration.”

 

2.
Except as expressly amended by this Amendment, all other provisions of the Agreement shall remain unchanged and in full force
and effect. Unless amended or first defined by this Amendment, all capitalized terms have the meanings ascribed to them in the
Agreement. In the event of conflict between the terms of this Amendment and the Agreement, the terms of this Amendment shall control.

 

3.
This Amendment may be executed (including via facsimile signatures) by the Parties in any
number of counterparts, each of which when so executed and delivered shall be deemed to be an original, but all of which shall
constitute one and the same agreement, binding on the Parties as if each had signed the same document.

 

Signature
page follows

 

    	 	 	 

    	 

    

 

IN
WITNESS WHEREOF, the duly authorized representatives of the Parties have signed this Amendment as of the dates set forth below.

 

	ENCORE
    CLINICAL, INC.	 	RAZOR
    GENOMICS, INC.
	 	 	 	 	 
	By:	/s/
    David Jablons	 	By:	/s/
    Michael Mann
	Name:	David
    Jablons	 	Name:	Michael
    Mann
	Title:	Director	 	Title:	CEO
	Date:	September
    15, 2016	 	Date:	September
    15, 2016

 

    	 	 	 

    	 

    

 

SECOND
AMENDMENT TO THE LABORATORY AGREEMENT

 

This
is a second Amendment (“Second Amendment”) to that certain Laboratory Agreement (the “Agreement”)
dated August 15, 2015 and amended September 15, 2016, between Encore Clinical, Inc., a Delaware corporation (“Encore”),
and Razor Genomics, Inc., a Delaware corporation (“Razor”). Each of Encore and Razor is hereinafter referred
to as a “Party” and collectively as the “Parties”.

 

WHEREAS,
the Parties desire to amend the Agreement as set forth herein.

 

NOW
THEREFORE, in consideration of the foregoing premises and certain other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Parties hereto further agree as follows:

 

1.
Article 3 of the Agreement shall be deleted and replaced in its entirety with the following:

 

ARTICLE
3

 

LABORATORY
MANAGEMENT PAYMENTS

 

3.1
Payments. To support Encore’s ongoing management of the CLIA Laboratory as outlined in Section 3.3 of this Agreement,
Razor shall make the following payments to Encore (the “Laboratory Management Payments”):

 

3.2
Timing of Laboratory Management Payments. Payments due to Encore pursuant to Section 3.1 shall be paid in full by Razor
to Encore’s designated bank account within thirty (30) days after the occurrence of the applicable due date set forth above.

 

	 	 	Payment
    due date	 	Amount
    due
	(a)	 	Effective
    Date	 	USD
    450,000
	(b)	 	The
    first anniversary of the Effective Date	 	USD
    300,000
	(c)	 	The
    second anniversary of the Effective Date	 	USD
    325,000

 

    	 	 	 

    	 	 	 

    

 

3.3
Services Rendered. Encore’s ongoing management of the CLIA Laboratory shall encompass the following services:

 

(a)
Lab maintenance (including routine equipment maintenance and provision of routine supplies, but not including equipment replacement,
new equipment purchases or provision of supplies for assay validation or re-calibration)

 

(b)
Assay maintenance (including QC and proficiency testing, and record keeping as required by CLIA regulations)

 

(c)
Regulatory compliance

 

(d)
Clinical performance of the assay (including reporting and all communication with requesting physicians and other providers)

 

2.
Section 9.1 of the Agreement shall be deleted and replaced in its entirety with the following:

 

9.1
Term. This Agreement shall be effective as of the Effective Date and, unless earlier terminated in accordance with other
provisions herein, shall remain in effect until September 14, 2018 (the “Term”).

 

3.
Except as expressly amended by this Amendment, all other provisions of the Agreement shall remain unchanged and in full force
and effect. Unless amended or first defined by this Amendment, all capitalized terms have the meanings ascribed to them in the
Agreement. In the event of conflict between the terms of this Amendment and the Agreement, the terms of this Amendment shall control.

 

4.
This Amendment may be executed (including via facsimile signatures) by the Parties in any number of counterparts, each of which
when so executed and delivered shall be deemed to be an original, but all of which shall constitute one and the same agreement,
binding on the Parties as if each had signed the same document.

 

Signature
page follows

 

    	 	 	 

    	 	 	 

    

 

IN
WITNESS WHEREOF, the duly authorized representatives of the Parties have signed this Amendment as of the dates set forth below.

 

	ENCORE
    CLINICAL, INC. 	 	RAZOR
    GENOMICS, INC.
	 	 	 	 	 
	By:
    	/S/
    David Jablons	 	By:	/S/
    Michael Mann
	Name:	David
    Jablons	 	Name:	Michael
    Mann
	Title:	Director	 	Title:	CEO
	Date	3/6/2018	 	Date	3/6/2018

 

    	 	 	 

    	 	 	 

    

 

AMENDMENT
TO THE CLIA LABORATORY COLLABORATION AGREEMENT

 

This
is an
Amendment (“Amendment”) to that certain CLIA Laboratory Collaboration Agreement (the “Agreement”)
dated April 1, 2015, among Encore Clinical, Inc., a Delaware corporation (“Encore”), and CureSeq, Inc., a Delaware
corporation (“CureSeq”). Each of Encore and Razor is hereinafter
referred to as a “Party” and collectively as the “Parties”.

 

WHEREAS,
the Parties desire to amend the Agreement as set forth herein.

 

NOW
THEREFORE, in consideration of the foregoing premises and certain other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Parties hereto further agree as follows:

 

1. Section
2.2 of the Agreement shall be deleted and replaced in its entirety with the following:

 

2.2
Establishment of the Laboratory. Encore shall be responsible for all aspects of establishment and management of the Laboratory,
including equipment costs, supply and reagent costs, and personnel. Encore shall also provide monthly payments of $10,000.00 to
CureSeq in support of this collaboration. CureSeq shall provide guidance and technical support at the request of Encore where
appropriate.

 

2. Section
9.1 of the Agreement shall be deleted and replaced in its entirety with the following:

 

9.1
Term. This Agreement shall be effective as of the Effective Date and, unless
earlier terminated in accordance with other provisions herein, shall remain in effect
until the tenth anniversary of the Effective Date (the “Term”). Upon expiration of the Term, Encore shall have
the right to renew the Agreement for an additional period of five years.

 

3. Except
as expressly amended by this Amendment, all other provisions of the Agreement shall remain unchanged and in full force and
effect. Unless amended or first defined by this Amendment, all capitalized
terms have the meanings ascribed to them in the Agreement. In the event of conflict
between the terms of this Amendment and the Agreement, the terms of this Amendment
shall control.

 

4. This
Amendment may be executed (including via facsimile
signatures) by the Parties in any number of counterparts, each of which when so executed
and delivered shall be deemed to be an original, but all of which shall constitute
one and the same agreement, binding on the Parties as if each had signed the same
document.

 

Signature
page follows

 

    	 	 	 

    	 

    

 

IN
WITNESS WHEREOF, the
duly authorized representatives of the Parties have signed this Amendment as of the dates set forth below.

 

	ENCORE
    CLINICAL, INC.	 	RAZOR
    GENOMICS, INC.
	 	 	 	 	 
	By:	/s/
    David Jablons	 	By:	/s/
    Michael Mann
	Name:	David
    Jablons	 	Name:	Michael
    Mann
	Title:	Director	 	Title:	CEO
	Date	August
    1, 2018	 	Date	August
    1, 2018

 

    	 	 	 

    	 

    

 

 

Certain
identified information has been omitted because the omitted information is (i) not material and (ii) would likely cause competitive
harm to OncoCyte Corporation if publicly disclosed. Omitted portions of this exhibit are marked [**].

 

Execution
Copy

 

FOURTH
AMENDMENT TO LABORATORY AGREEMENT

 

This
Fourth Amendment to Laboratory Agreement (this “Fourth Amendment”) is made and entered into effective as of
September 30, 2019 (the “Effective Date”), by and among (i) Encore Clinical, Inc., a Delaware corporation (“Encore”),
(ii) Razor Genomics, Inc., a Delaware corporation (“Razor”), and (iii) OncoCyte Corporation, a California corporation
(“OncoCyte”). Each of Encore, Razor and OncoCyte are hereinafter referred to as a “Party”
and collectively as the “Parties”.

 

WHEREAS,
Encore and Razor are parties to that certain Laboratory Agreement, dated as of August 15, 2015, as amended by the Amendment to
Laboratory Agreement on September 15, 2016, the Second Amendment to Laboratory Agreement on March 6, 2018 and the Third Amendment
to Laboratory Agreement on August 1, 2018 (the “Laboratory Agreement”);

 

WHEREAS,
pursuant to that certain Subscription and Stock Purchase Agreement, dated as of September 4, 2019 (as amended from time to time
in accordance with the terms thereof, the “Purchase Agreement”), by and among the Parties, the Parties agreed
that, among other matters, as a condition to the consummation of the initial closing thereunder, the Parties will enter into a
Sublicense and Distribution Agreement in substantially the form attached as Exhibit D thereto (the “License Agreement”),
and a Development Agreement in substantially the form attached as Exhibit E thereto (the “Development Agreement”),
each of which contemplates, among other matters, that prior to such initial closing, the Parties will amend the Laboratory Agreement
to have OncoCyte become a party to the Laboratory Agreement and otherwise on the terms set forth below.

 

NOW
THEREFORE, in consideration of the foregoing premises and certain other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Parties hereto further agree as follows:

 

1. Definitions.

 

(a) The
capitalized terms in the preamble and recitals hereto are hereby incorporated into the Laboratory Agreement as if they were fully
set forth therein.

 

(b) Capitalized
terms used but not defined in this Fourth Amendment will have the meanings ascribed to such terms in the Laboratory Agreement,
or if not defined therein, in the License Agreement, or if not defined therein, in the Development Agreement, or if not defined
therein, in the Purchase Agreement.

 

(c) The
definition of “Business Day” in Article I of the Laboratory Agreement is hereby amended to replace “New York,
New York” with “the State of California”.

 

(d) The
definition of “Laboratory Services” in Article I of the Laboratory Agreement is hereby amended to add the following
immediately prior to the period at the end thereof: “, including those services described in Section 3.3 hereof”.

 

2. Acknowledgement
of Exercise of Laboratory Acquisition Option. Encore and Razor acknowledge that the Laboratory Acquisition Option was
previously exercised by Razor during the Option Period, and that Razor acquired the CLIA Laboratory and the Laboratory Assets
in accordance with Article 2 of the Laboratory Agreement.

 

    	 	 	 

    	 

    

 

3. Amendment
to Laboratory Management Payments. Article 3 of the License Agreement is hereby deleted and replaced in its entirety with
the following:

 

article
3

LABORATORY MANAGEMENT PAYMENTS; LABORATORY SERVICES

 

3.1 Payments.
To support Encore’s ongoing management of the CLIA Laboratory and provision of the Laboratory Services as outlined in Section
3.3 of this Agreement, during the Term OncoCyte shall pay to Encore an annual fee of [**], payable in monthly installments of
[**] per month (the “Laboratory Management Payments”). 

 

3.2 Timing
of Laboratory Management Payments. Payments due to Encore pursuant to Section 3.1 shall be paid in full by OncoCyte to Encore’s
designated bank account, as set forth on Exhibit A hereto (or to such other bank account as Encore may designate in writing
to OncoCyte after the date hereof), in monthly installments in arrears of [**] within thirty (30) days after the Effective Date
and after the end of each monthly anniversary of the Effective Date during the Term. For any portion of the Term that is less
than a full month, the monthly Laboratory Management Payment will be pro-rated based on the number of days in the Term as a percentage
of the number of days in the month.

 

3.3 Laboratory
Services. Encore’s ongoing management of the CLIA Laboratory and the Laboratory Services provided under this Laboratory
Agreement shall include the following services:

 

(a) Lab
maintenance (including routine equipment maintenance and provision of routine supplies, but not including equipment replacement,
new equipment purchases, or provision of supplies for assay validation or re-calibration);

 

(b) Assay
maintenance (including Quality Control and proficiency testing, and record keeping as required by CLIA regulations);

 

(c) Regulatory
compliance;

 

(d) At
the minimum, Encore shall provide the following staffing:

 

(i) One
Clinical Laboratory Scientist (“CLS”) working 60% of a full-time equivalent to manage all daily operational, quality
assurance and quality control functions; any additional CLS personnel are to be provided by OncoCyte as needed;

 

(ii) One
laboratory director;

 

(iii) One
domain expert and technical/clinical consultant;

 

(iv) One
technical supervisor, CLIA regulatory expert consultant;

 

(e) Clinical
performance of the Assay (including reporting and all communication with requesting physicians and other providers); OncoCyte
shall be responsible for the cost of procuring all reagents and consumables required to perform the Assay; and

 

(f) Subject
to landlord consent, Razor and Buyer shall be provided access and use of the facility located at 150 North Hill Dr., Brisbane,
CA 94005 (the “Brisbane Facility”) for all activities at OncoCyte’s discretion;

 

    	 	2	 

    	 

    

 

3.4 Additional
Services. If OncoCyte reasonably determines that Encore needs to perform additional support or services not included as Laboratory
Services in the Laboratory Agreement, then if requested by OncoCyte, the Parties will negotiate in good faith an additional addendum
to this Laboratory Agreement pursuant to which Encore will provide such services and OncoCyte shall pay to all Encore its reasonable
documented out-of-pocket incremental costs related to the provision of such additional support or services.

 

3.5 Use
and Costs of Facility

 

(a) Notwithstanding
anything to the contrary contained in the Laboratory Agreement, (i) OncoCyte will not be required to assume any lease of Razor
or Encore for the CLIA Laboratory, (ii) OncoCyte will be entitled to lease laboratory space to Razor for performance of the Assay
in support of the Clinical Trial or of any related commercialization of the Assay, (iii) OncoCyte may charge market rent for such
space leased pursuant to clause (ii) above up to a maximum of [**], provided that OncoCyte shall assume the costs of transferring
the CLIA Laboratory to OncoCyte laboratories, and (iv) if such costs for transferring the CLIA Laboratory are assumed pursuant
to clause (iii) above, OncoCyte will assume any costs solely related to subletting and/or early termination of the Brisbane Facility
lease for the CLIA Laboratory as incurred either by CureSeq, Inc., Encore or Razor.

 

(b) OncoCyte
will pay for any modifications of the CLIA Laboratory that OncoCyte requires. 

 

(c) Encore
shall arrange for or compensate OncoCyte for removal of biological waste on site in the CLIA Laboratory as of the Effective Date.
OncoCyte shall be responsible for the removal of biological waste generated in the CLIA Laboratory after the Effective Date.

 

(d) The
CLIA Laboratory shall not be used for any activities other than the Clinical Trial and the commercialization of the Razor Assay
as contemplated by the Development Agreement and the License Agreement without the express written permission of OncoCyte. 

 

3.6 Laboratory
Expenses and Clinical Trial Expense Reserve. The Parties acknowledge and agree that none of the expenses incurred by any of
the Parties under or in connection with the Laboratory Agreement will be included as Clinical Trial expenses covered under the
Clinical Trial Expense Reserve, including additional services as contemplated by Section 3.4 above, or otherwise required to be
paid by OncoCyte under the Development Agreement.

 

3.7 Laboratory
of Record. Razor hereby agrees that it will serve as the laboratory of record for the Razor Assay (i.e., the test report will
state “Test performed at Razor Genomics Inc.”).

 

4. Amendment
to Intellectual Property Rights. The Parties hereby amend Section 4.1 of the License Agreement so that all intellectual
property rights in any and all Inventions that are conceived or reduced to practice in connection with the Laboratory Agreement
after the Effective Date will be jointly owned by OncoCyte and Razor, and are hereby assigned to OncoCyte and Razor as joint owners.
OncoCyte and Razor hereby grant Encore a limited, non-exclusive, royalty-free license to use such Inventions solely for purposes
of carrying out work under the Laboratory Agreement and the Consulting Agreement.

 

5. Amendment
to Implied Warranties. The Parties hereby amend Section 7.3 of the Laboratory Agreement to add (a) the following immediately
after “WARRANTIES” in the third line thereof “IN THIS AGREEMENT” and (b) the following immediately after
“DISCLAIMS” in the fifth line thereof “, SOLELY FOR PURPOSES OF THIS AGREEMENT,”.

 

    	 	3	 

    	 

    

 

6. Amendment
to Indemnification Provisions.

 

(a) Section
8.1 of the Laboratory Agreement is hereby deleted in its entirety and replaced with the following:

 

“8.1 Indemnity.

 

(a) Encore
shall indemnify, defend and hold harmless each of OncoCyte and Razor and their respective Affiliates, directors, officers, employees
and agents from and against any and all costs, damages, liabilities, losses or expenses (including reasonable legal fees and expenses)
in connection with claims or actions brought by third parties (collectively, “Losses”) to the extent arising
from the breach by or on behalf of Encore of its warranties or obligations under the Laboratory Agreement, or the negligence,
gross negligence or willful misconduct of Encore, its Affiliates, directors, officers, employees, independent contractors, licensees
or agents in connection with the Laboratory Agreement. 

 

(b) Razor
shall indemnify, defend and hold harmless each of OncoCyte and Encore and their respective Affiliates, directors, officers, employees
and agents from and against any and all Losses to the extent arising from the breach by or on behalf of Razor of its warranties
or obligations under the Laboratory Agreement, or the negligence, gross negligence or willful misconduct of Razor, its Affiliates,
directors, officers, employees, independent contractors, licensees or agents in connection with the Laboratory Agreement.

 

(c) OncoCyte
shall indemnify, defend and hold harmless each of Razor and Encore and their respective Affiliates, directors, officers, employees
and agents from and against any and all Losses to the extent arising from the breach by or on behalf of OncoCyte of its warranties
or obligations under the Laboratory Agreement, or the negligence, gross negligence or willful misconduct of OncoCyte, its Affiliates,
directors, officers, employees, independent contractors, licensees or agents in connection with the Laboratory Agreement.”

 

(b) Section
8.2 of the Laboratory Agreement is hereby deleted in its entirety and replaced with the following: “[RESERVED].

 

7. Amendment
to Term. Section 9.1 of the Agreement shall be deleted and replaced in its entirety with the following:

 

“9.1 Term.
This Agreement shall be effective as of the Effective Date and, unless earlier terminated in accordance with other provisions
herein, shall remain in effect until the second anniversary of the Effective Date (the “Term”); provided, that
OncoCyte, at its sole discretion, shall have the right to extend the Term of this Agreement for an unlimited number of successive
additional one year terms by providing written notice thereof to Razor and Encore no less than sixty (60) days prior to the end
of the then expiring Term, and provided that OncoCyte agrees to negotiate in good faith an increase in Laboratory Management Payments
for such extended one-year Term in response to a reasonable demonstration by Encore of an increase in its costs to provide the
Laboratory Services.”

 

8. Amendment
to Termination Rights. Article 9 of the Laboratory Agreement is hereby amended to renumber Section 9.4 therein as Section
9.5 and add the following new Section 9.4:

 

    	 	4	 

    	 

    

 

“9.4 Additional
OncoCyte Termination Rights.

 

(a) Upon
the consummation of the Second Closing pursuant to the Purchase Agreement, OncoCyte shall have the right, at its sole election,
to terminate the Laboratory Agreement without penalty by providing written notice thereof to Encore and Razor. Without limiting
the foregoing, if requested in writing by OncoCyte to Encore and Razor after the consummation of the Second Closing, Encore and
Razor will negotiate in good faith such amendments to the Laboratory Agreement as reasonably requested by OncoCyte.

 

(b) OncoCyte
shall have the right, at its sole election, to terminate the Laboratory Agreement without penalty by providing written notice
thereof to Encore and Razor if there is an event or occurrence that adversely affects, in any material respect, the Razor Assay
or its prospects or its ability to be commercialized, and it remains continuing and uncured.

 

9. Amendment
to Miscellaneous Provisions.

 

(a) Section
10.4 of the Laboratory Agreement is hereby amended to (i) delete the references to “Investor” therein and replace
it with the term “Party” and (ii) add the following additional sentence at the end thereof: “This Laboratory
Agreement is for the sole benefit of the Parties and their successors and permitted assigns and nothing herein, expressed or implied
shall give or be construed to give any Person, other than the Parties and such successors and permitted assigns, any legal or
equitable rights hereunder.”.

 

(b) Section
10.5 of the Laboratory Agreement is hereby deleted in its entirety and replaced with the following:

 

“10.5 Notices.
Any notice, request, instruction or other document to be given hereunder by a Party hereto shall be in writing and shall be deemed
to have been given, (i) when received if given in person or by courier or a courier service, (ii) on the date of transmission
if sent by facsimile or email (with affirmative confirmation of receipt, and provided, that the Party providing notice shall within
two (2) Business Days provide notice by another method under this Section 10.5 or (iii) three (3) Business Days after being
deposited in the U.S. mail, certified or registered mail, postage prepaid:

 

	If
    to Encore or, at or prior to the Second Closing, Razor, to:	 	with
    a copy (which will not constitute notice) to:
	 	 	 
	Razor
    Genomics Inc.	 	Latham
    & Watkins LLP
	150
    N. Hill Drive, Suite 14	 	140
    Scott Drive
	Brisbane,
    CA 94005	 	Menlo
    Park, CA 94025
	Attn:
    Michael Mann, CEO	 	Attn:
    Benjamin A. Potter, Esq.
	Telephone
    No: [**]	 	Facsimile
    No.: [**]
	Email:
    [**]	 	Telephone
    No: [**]
	 	 	Email:
    [**]
	 	 	 
	If
    to OncoCyte or, after the Second Closing, Razor, to:	 	with
    a copy (which will not constitute notice) to:
	 	 	 
	OncoCyte
    Corporation	 	Ellenoff
    Grossman & Schole LLP
	1010
    Atlantic Avenue, Suite 102	 	1345
    Avenue of the Americas, 11th Floor
	Alameda,
    California 94501	 	New
    York, New York 10105
	Attn:
    Albert P. Parker, COO	 	Attn: Matthew
    A. Gray, Esq.;
	Telephone
    No: [**]	 	 Robert
    Charron, Esq.
	Email:
    [**]	 	Facsimile
    No.: [**]
	 	 	Telephone
    No.: [**]
	 	 	Email: [**]

 

or
to such other individual or address as a party hereto may designate for itself by notice given as herein provided.

 

    	 	5	 

    	 

    

 

(c) Section
10.6 of the Laboratory Agreement is hereby deleted in its entirety and replaced with the following:

 

“10.6 Governing
Law; Jurisdiction; Waiver of Jury Trial. This Laboratory Agreement shall be
governed by, and construed in accordance with, the laws of the State of Delaware (without giving effect to its choice of law principles).
Subject to Section 10.7, for purposes of any dispute, action, claim, litigation or other legal proceeding (a “Proceeding”)
arising out of or in connection with this Laboratory Agreement, or any transaction contemplated hereby, each of the Parties (a)
irrevocably submits to the exclusive jurisdiction and venue of any state or federal court located in the State of California (and
any appellate courts thereof), (b) agrees that service of any process, summons, notice or document by U.S. registered mail to
such Party’s respective address set forth in Section 10.5 shall be effective service of process for any Proceeding
with respect to any matters to which it has submitted to jurisdiction in this Section 10.6, and (c) waives and covenants
not to assert or plead, by way of motion, as a defense or otherwise, in any such Proceeding, any claim that it is not subject
personally to the jurisdiction of such court, that the Proceeding is brought in an inconvenient forum, that the venue of the Proceeding
is improper or that this Laboratory Agreement or the subject matter hereof may not be enforced in or by such court, and hereby
agrees not to challenge such jurisdiction or venue by reason of any offsets or counterclaims in any such Proceeding. The
Parties hereby knowingly, voluntarily and intentionally waive the right any may have to a trial by jury in respect to any litigation
based hereon, or arising out of, under, or in connection with this Laboratory Agreement and any agreement contemplated to be executed
in connection herewith, or any course of conduct, course of dealing, statements (whether verbal or written) or actions of any
Party in connection with such agreements.”

 

(d) Section
10.7 of the Laboratory Agreement is hereby deleted in its entirety and replaced with the following:

 

“10.7 Arbitration.
Any and all disputes, controversies and claims (other than applications for a temporary restraining order, preliminary injunction,
permanent injunction or other equitable relief or application for enforcement of a resolution under this Section 10.7)
arising out of, related to, or in connection with this Laboratory Agreement or the transactions contemplated hereby (a “Dispute”)
shall be governed by this Section 10.7. A Party must, in the first instance, provide written notice of any Disputes to
the other Parties subject to such Dispute, which notice must provide a reasonably detailed description of the matters subject
to the Dispute. The Parties involved in such Dispute shall seek to resolve the Dispute on an amicable basis within twenty (20)
days of the notice of such Dispute being received by such other Parties subject to such Dispute; the “Resolution Period”);
provided, that if any Dispute would reasonably be expected to have become moot or otherwise irrelevant if not decided within
sixty (60) days after the occurrence of such Dispute, then there shall be no Resolution Period with respect to such Dispute. Any
Dispute that is not resolved during the Resolution Period may immediately be referred to and finally resolved by arbitration pursuant
to the then-existing Expedited Procedures (as defined in the AAA Procedures) of the Commercial Arbitration Rules (the “AAA
Procedures”) of the American Arbitration Association (the “AAA”). Any Party involved in such Dispute
may submit the Dispute to the AAA to commence the proceedings after the Resolution Period. To the extent that the AAA Procedures
and this Laboratory Agreement are in conflict, the terms of this Laboratory Agreement shall control. The arbitration shall be
conducted by one arbitrator nominated by the AAA promptly (but in any event within five (5) Business Days) after the submission
of the Dispute to the AAA and reasonably acceptable to each Party subject to the Dispute, which arbitrator shall be a commercial
lawyer with substantial experience arbitrating disputes under laboratory services agreements. The arbitrator shall accept his
or her appointment and begin the arbitration process promptly (but in any event within five (5) Business Days) after his or her
nomination and acceptance by the Parties subject to the Dispute. The proceedings shall be streamlined and efficient. The arbitrator
shall decide the Dispute in accordance with the substantive law of the State of Delaware. Time is of the essence. Each Party subject
to the Dispute shall submit a proposal for resolution of the Dispute to the arbitrator within twenty (20) days after confirmation
of the appointment of the arbitrator. The arbitrator shall have the power to order any Party to do, or to refrain from doing,
anything consistent with this Laboratory Agreement, the Purchase Agreement, the Development Agreement, the License Agreement,
the Consulting Agreement and applicable law, including to perform its contractual obligation(s); provided, that the arbitrator
shall be limited to ordering pursuant to the foregoing power (and, for the avoidance of doubt, shall order) the relevant Party
(or Parties, as applicable) to comply with only one or the other of the proposals. The arbitrator’s award shall be in writing
and shall include a reasonable explanation of the arbitrator’s reason(s) for selecting one or the other proposal. The seat
of arbitration shall be in the State of California, and the language of the arbitration shall be English.”

 

    	 	6	 

    	 

    

 

(e) Article
10 of the Laboratory Agreement is hereby amended to add the following new Section 10.12:

 

“10.12 Remedies.
Except as specifically set forth in this Laboratory Agreement, any Party having any rights under any provision of this Laboratory
Agreement will have all rights and remedies set forth in this Laboratory Agreement and all rights and remedies which such Party
may have been granted at any time under any other contract or agreement and all of the rights which such Party may have under
any applicable law. Except as specifically set forth in this Laboratory Agreement, any such Party will be entitled to (a) seek
to enforce such rights specifically, without posting a bond or other security or proving damages or that monetary damages would
be inadequate, (b) to recover damages by reason of a breach of any provision of this Laboratory Agreement and (c) to exercise
all other rights granted by applicable law. The exercise of any remedy by a Party will not preclude the exercise of any other
remedy by such Party.”

 

10. Miscellaneous.
Except as expressly provided in this Fourth Amendment, all of the terms and provisions of the Laboratory Agreement are and
shall remain in full force and effect, on the terms and subject to the conditions set forth therein. This Fourth Amendment does
not constitute, directly or by implication, an amendment, modification or waiver of any provision of the Laboratory Agreement,
or any other right, remedy, power or privilege of any party to the Laboratory Agreement, except as expressly set forth herein.
Any reference to the Laboratory Agreement in the Laboratory Agreement or any other agreement, document, instrument or certificate
entered into or issued in connection therewith shall hereinafter mean the Laboratory Agreement, as amended or modified by this
Fourth Amendment (or as the Laboratory Agreement may be further amended or modified after the date hereof in accordance with the
terms thereof). The Laboratory Agreement, as amended and modified by this Fourth Amendment (together with the Purchase Agreement,
the Development Agreement, the License Agreement and the Consulting Agreement to the extent applicable), constitutes the entire
agreement between the parties with respect to the subject matter of the Laboratory Agreement, as amended by this Fourth Amendment,
and supersedes all prior agreements and understandings, both oral and written, between the parties with respect to its subject
matter. In the event of any conflict between the terms of this Fourth Amendment and the Laboratory Agreement, the terms of this
Fourth Amendment shall control. The provisions of Article 10 of the Laboratory Agreement (other than Section 10.1), as amended
by this Fourth Amendment, are hereby incorporated herein by reference and apply to this Fourth Amendment as if all references
to the “Laboratory Agreement” contained therein were instead references to this Fourth Amendment. The terms of this
Fourth Amendment shall be interpreted, enforced, governed by and construed in a manner consistent with the provisions of the Laboratory
Agreement, as amended by this Fourth Amendment.

 

{Remainder
of Page Intentionally Left Blank; Signature Page Follows}

 

    	 	7	 

    	 

    

 

IN
WITNESS WHEREOF, the duly authorized representatives of the Parties have signed this Fourth Amendment effective as of the date
first set forth above.

 

	ENCORE
    CLINICAL, INC.	 	RAZOR
    GENOMICS, INC.
	 	 	 
	By:	/s/
    Michael Mann	 	By:	/s/
    Michael Mann
	Name:	Michael
    Mann	 	Name:	Michael
    Mann
	Title:	Chief
    Executive Officer	 	Title:	Chief
    Executive Officer
	 	 	 	 	 
	ONCOCYTE
    CORPORATION	 	 
	 	 	 
	By:	/s/
    Ron A. Andrews	 	 	 
	Name:	Ron
    A. Andrews	 	 	 
	Title:	Chief
    Executive Officer	 	 	 

 

{Signature
Page to Fourth Amendment to Laboratory Agreement}

 

    	 	 	 

    	 

    

 

Exhibit
A

Designated
Encore Bank Account

 

	Bank Name:	[**]
	Account Holder:	[**]
	Account Number:	[**]
	ABA Routing Number:	[**]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]